The short version of hexenoyl cap fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
A mixed dose commonly combines regular insulin, which is fast acting, with a longer acting insulin such as NPH. A mixed dose insulin schedule may be prescribed to provide both short-term and long-term coverage. mmol/L Millimoles per litre. The world-standard (excepting the US) designated SI unit for the measurement of blood sugar levels. It is the concentration by molecular weight in a set amount of liquid. Mononeuropathy A form of diabetic neuropathy affecting a single nerve. The eye is a common site for this form of nerve damage. See also: Neuropathy. Morbidity rate the rate at which Mortality rate the rate at which death occurs (usually used as a statistical shorthand in regard to an infection or other condition). Myocardial infarction heart attack. The words mean heart muscle blockage. Myo-inositol A substance in the cell that is thought to play a role in helping the nerves to work. Low levels of myo-inositol may be involved in diabetic neuropathy.
Annex II to the Convention on the Physical Protection of Nuclear Material 1980 (which became operative on 8 February 1997) classifies DU as a category II nuclear material. Storage and transport rules are set down for that category which indicates that DU is considered sufficiently "hot" and dangerous to warrant these protections. But since weapons containing DU are relatively new weapons no treaty exists yet to regulate, limit or prohibit its use. The legality or illegality of DU weapons must therefore be tested by recourse to the general rules governing the use of weapons under humanitarian and human rights law which have already been analysed in Part I of this paper, and more particularly at paragraph 35 which states that parties to Protocol I to the Geneva Conventions of 1949 have an obligation to ascertain that new weapons do not violate the laws and customs of war or any other international law. As mentioned, the International Court of Justice considers this rule binding customary humanitarian law. Louise Arbour, chief prosecutor for the International Criminal Tribunal for the Former Yugoslavia led a committee of staff lawyers to investigate possible treaty prohibitions against the use of DU in weapons. Their findings were that:
== Biochemistry == A1 receptors are implicated in sleep promotion by inhibiting wake-promoting cholinergic neurons in the basal forebrain. A1 receptors are also present in smooth muscle throughout the vascular system. In humans, the adenosine A1 receptor has been found to be most highly expressed in the brain, with lower expression in other tissues such as the testis, pancreas, and heart.
Sources: en.wikipedia.org
=== Studies of folding with high time resolution === The study of protein folding has been greatly advanced in recent years by the development of fast, time-resolved techniques. Experimenters rapidly trigger the folding of a sample of unfolded protein and observe the resulting dynamics. Fast techniques in use include ultrafast mixing of solutions, photochemical methods, and laser temperature jump spectroscopy. Among the many scientists who have contributed to the development of these techniques are Heinrich Roder, Terry Oas, Harry Gray, Martin Gruebele, Brian Dyer, William Eaton, Sheena Radford, Chris Dobson, Alan Fersht, Bengt Nölting and Lars Konermann.
In September 2015, chairman Russ Withers and chief executive Warren Wilmot announced they were resigning from the company. Deputy chairman Michael Smith replaced Withers, while Bob Baily was appointed as interim chief executive. In December 2015, Stewart Levitt of law firm Levitt Robinson Solicitors, who featured prominently in the Four Corners program, announced a potential class action lawsuit against 7-Eleven head office on behalf of franchisees who had allegedly been lured into signing on with 7-Eleven by false representations. This announcement was made on the same day as a Court finding describing Levvit Robinson's "hellish bullying" of Dr Brendan French, miring the action in controversy. Also on that day, 7-Eleven offered to pay "the first $25 million of back-pay claims brought by current and former workers. Franchisees would then pay the next $5 million and any payments after that would be split 50-50 between head office and franchisees." Fels "described the $25 million offer from head office as a 'significant step forward'" but added that his panel's investigation would not be effected. 7-Eleven ultimately paid more than $173 million for "systematic wage theft" to workers employed between 2015 and 2020. Levvit Robinson was forced to retract misleading statements made in advertising to 7-Eleven franchisees in June 2018 by the Federal Court of Australia. This occurred only months after Levvit Robinson launched a new class action against 7-Eleven that included the ANZ Bank despite banks having stopped loans to 7-Eleven franchisees in 2015.
== Types of human remains in museums == Museum collections contain human remains in diverse forms, including entire preserved bodies, discrete parts of the anatomy, and even art and artifacts created out of human body parts.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。